Methods and systems for determining a likelihood of adverse prostate cancer pathology
US9790557B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2015 |
| Grant date | Oct 17, 2017 |
| Priority date | — |
| Expiry date | Apr 14, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/178
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
The present disclosure provides methods that find use in determining a likelihood of adverse prostate cancer pathology in a subject. The methods generally involve detection of one or more diagnostic microRNAs (miRNAs), such as mir-19a, mir-19b, mir-519c-5p, and/or mir-345 in a biological sample from the subject, such as blood or blood product. The detection of one or more such diagnostic miRNAs can be used to determine a likelihood of adverse prostate cancer pathology in a subject. The methods of the present disclosure also find use in facilitating treatment decisions for a subject. Also provided are devices, systems, and kits that may be used in practicing methods of the present disclosure.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.